Provention Bio, Inc. (PRVB)

$ 6.21
0.00 (0.00%)
Neutral
Symbol PRVB
Price $ 6.21
Beta 2.963
Volume Avg. 0.51M
Market Cap 0.39B
Shares () -
52 Week Range 5.59-20.05
1y Target Est -
DCF Unlevered PRVB DCF ->
DCF Levered PRVB LDCF ->
ROE -85.29% Strong Sell
ROA -68.44% Strong Sell
Operating Margin -
Debt / Equity 16.00% Neutral
P/E -
P/B 2.49 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PRVB news


Mr. Ashleigh Palmer
Healthcare
Biotechnology
Nasdaq Global Select

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.